Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Haematologica

Volumn 101, Issue 5, 2016, Pages e185-e188

  Reis, Bernhard ^a   Jukofsky, Lori ^b   Chen, Gong ^b   Martinelli, Giovanni ^c   Zhong, Hua ^b   Venus So, W ^b   Dickinson, Michael J ^d   Drummond, Mark ^e   Assouline, Sarit ^f   Hashemyan, Maneja ^b   Theron, Michel ^a   Blotner, Steven ^b   Lee, Je Hwan ^g   Kasner, Margaret ^h   Yoon, Sung Soo ⁱ   Rueger, Ruediger ^j   Seiter, Karen ^k   Middleton, Steven A ^b   Kelly, Kevin R ^l   Vey, Norbert ^m   Yee, Karen ⁿ   Nichols, Gwen ^b   Chen, Lin Chi ^b   Pierceall, William E ^b   more..

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Roche Pharma Research and Early Development   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f MCGILL UNIVERSITY   (Canada)

^g University of Ulsan College of Medicine   (South Korea)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ Seoul National University College of Medicine   (South Korea)

^j Roche Pharma Research and Early Development   (Germany)

^k NEW YORK MEDICAL COLLEGE   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m INSTITUT PAOLI CALMETTES   (France)

ⁿ PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

AML; Complementary diagnostics; Flow cytometry; Idasanutlin; MDM2 antagonism

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CYTARABINE; IDASANUTLIN; PROTEIN MDM2; 4 AMINOBENZOIC ACID DERIVATIVE; MDM2 PROTEIN, HUMAN; PYRROLIDINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; BLAST CELL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; LETTER; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; ACUTE MYELOID LEUKEMIA; BIOSYNTHESIS; BLAST CELL CRISIS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; MALE; MORTALITY; PHASE 1 CLINICAL TRIAL;

BLAST CRISIS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PARA-AMINOBENZOATES; PROTO-ONCOGENE PROTEINS C-MDM2; PYRROLIDINES;

EID: 84964720949     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.139717     Document Type: Letter

References (9)

1. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM 2. Science. 2004;303(5659):844-848.
2. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA. 2006;103(6);1888-1893.
3. Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012; 13(11):1133-1140.
4. Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med. 2011;3(11):623-636.
5. Zhong H, Chen G, Jukofsky L, et al. MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia. Br J Haematol. 2015;171(3):432-435.
6. Jeay S, Gaulis S, Ferretti S, et al. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. eLife. 2015;e06498.
7. Yee K, Martinelli G, Vey N, et al. Phase 1/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients. Blood. 2014;124(21):116.
8. Andreeff M, Kelly KR, Yee K, et al. Results of the phase 1 trial of RG7112, a small molecule MDM2 antagonist in leukemia. Clin Cancer Res. 2015 Oct 12. [Epub ahead of print].
9. Milne C-P, Bryan C, Garafalo S, McKiernan M. Complementary versus companion diagnostics: apples and oranges? Biomark Med. 2015;9(1):25-34.